Buy & Sell ACADIA Pharmaceuticals Inc. (ACAD) – ACADIA Pharmaceuticals Inc. Price Today
Aura AI Summary
Key Stats
- $3.72BMarket Cap
- HealthSector
- -9.85%3M Drawdown
- $2.92BEnterprise Value
- -Dividend Yield
- 74 daysTypical Hold Time
ACADIA Pharmaceuticals Inc. (ACAD) is currently valued at a market capitalization of $3.72B, with an enterprise value of $2.92B. Over the past 52 weeks, ACADIA Pharmaceuticals Inc. has traded between a low of $20.06 and a high of $28.06, highlighting its annual price range. Over the past three months, ACADIA Pharmaceuticals Inc. has recorded a drawdown of -9.85%, reflecting recent price volatility. On average, investors hold ACADIA Pharmaceuticals Inc. for approximately 74 days, indicating typical investor behavior on the platform.
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Most Recent News
Investigation into Wealthfront's securities fraud continues amid sharp stock drops and deposit declines.
Glancy Prongay & Murray LLP is investigating Wealthfront Corporation for potential securities law violations after the company reported significant financial setbacks. Wealthfront's stock fell sharply following disclosures of large net deposit outflo...

ControlUp named Leader for third year in Gartner's 2026 Digital Employee Experience Magic Quadrant.
ControlUp has been recognized as a Leader for the third consecutive year in Gartner's 2026 Magic Quadrant for Digital Employee Experience (DEX) Management Tools. This highlights ControlUp's innovation in Autonomous Endpoint Management using agentic A...

Gilead and Merck halt lung cancer trial but report positive HIV drug Phase 3 results.
Gilead Sciences and Merck have stopped their Phase 3 trial combining Trodelvy and Keytruda for metastatic non-small cell lung cancer after it failed to show statistically significant benefits. However, they announced positive Phase 3 results for a ne...
